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Mesenchymal stem cells are present in many tissues of the human body, including amniotic fluid (AF) and dental
pulp (DP). Stem cells of bothAF andDP give rise to a variety of differentiated cells. In our experience, DP stem cells
(DPSCs) display a high capacity to produce bone. Therefore, our aim was to investigate if AF-derived stem cells
(AFSCs) were able to undergo bone differentiation in the presence of DPSCs. AFSCs were seeded under three
different conditions: (i) cocultured with DPSCs previously differentiated into osteoblasts; (ii) cultured in the
conditioned medium of osteoblast-differentiated DPSCs; (iii) cultured in the osteogenic medium supplemented
with vascular endothelial growth factor and bone morphogenetic protein-2 (BMP-2). Results showed that AFSCs
were positive for mesenchymal markers, and expressed high levels of Tra1-60, Tra1-80, BMPR1, BMPR2, and
BMP-2. In contrast, AFSCs were negative for epithelial and hematopoietic/endothelial markers. When AFSCs
were cocultured with DPSCs-derived osteoblasts, they differentiated into osteoblasts. A similar effect was
observed when AFSCs were cultured in the presence of a conditioned medium originated from DPSCs. We found
that osteoblasts derived fromDPSCs released large amounts of BMP-2 and vascular endothelial growth factor into
the culture medium and that those morphogens significantly upregulate RUNX-2 gene, stimulating osteogenesis.
This study highlights the mechanisms of osteogenesis and strongly suggests that the combination of AFSCs with
DPSCs may provide a rich source of soluble proteins useful for bone engineering purposes.
Introduction
Human mesenchymal stem cells (MSCs) are multi-potent cells that can differentiate into several lineages,
including bone, cartilage, muscle, tendon, ligament, fat, and
a variety of other connective tissues.1,2 Morphologically,
undifferentiated MSCs are spindle shaped and resemble fi-
broblasts. MSCs have been mostly identified in adult bone
marrow; recent reports have shown that MSCs are also
present in both adult and fetal peripheral blood, fetal liver,
fetal spleen, placenta, umbilical cord,3–5 Wharton’s Jelly,
dental pulp (DP),6–8 and amniotic fluid (AF).9–11
Lately, some reports evidenced that human AF contains a
variety of stem cells that are shed from embryonic and extra-
embryonic tissues during fetal development. Epithelial cells
derived from human AF can be transformed into neurons,
astrocytes, and oligodenrocytes, and these cells have been
indicated as possible candidates for transplantation therapy of
neurodegenerative diseases.12 Further, cells expressing the
stem cell marker Oct-4 were also found to be present in hu-
man AF. Due to this relevant feature, AF has been proposed
as an appealing source of multipotent stem cells that can be
used without the ethics concerns associated with human
embryonic stem cells.13 Therefore, AF might be a potentially
ideal source of MSCs for therapeutic transplantation.14
In previous studies we have demonstrated that MSCs
isolated from DP (DPSCs) coexpress the CD34 and CD117
markers,6–8,15,16 proliferate extensively, have a long lifespan,
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and maintain their multipotential capabilities for many
generations. In addition, DPSCs are capable of differentiating
into adipocytes, chondrocytes, and myocytes when cultured
with the adipo-condro-myogenic medium, and in osteoblasts
and bone when cultured in the standard medium supple-
mented with 20% fetal bovine serum (FBS) and without ad-
dition of specific osteogenic morphogens.6–8
Taking all the above into consideration, our aim was to
detect MSCs from AF and then to challenge them with
DPSCs to ascertain whether they could differentiate into a
bone tissue.
Materials and Methods
Culture of AF-derived MSCs
Amniotic fluid samples (n¼ 20, 20mL each) were obtained
by amniocentesis performed between 16 and 20 weeks of ges-
tation during routine prenatal diagnoses. Clinical indications
for amniocentesis were the advancedmaternal age, the familiar
or personal history of birth defects, and the risk that the fetus
might have a chromosome abnormality or an inherited con-
dition. The cytogenetic analyses revealed normal karyotypes
for all donors. Cellswere isolated from theAF samples nomore
than 4h before being used. The samples were centrifuged at
1300 rpm for 5min, and all the isolated cells were plated in
25 cm2 flasks containing low-glucose Dulbecco’s modified
Eagle’s medium (Invitrogen, Milan, Italy) supplemented with
100U/mL penicillin, 0.1mg/mL streptomycin, 10ng/mL
basic fibroblast growth factor, 10ng/mL epidermal growth
factor (all from Peprotech, Rocky Hill, NJ), and 20% FBS
(Invitrogen). The medium was renewed after the cells were
incubated at 378C with 5% humidified carbon dioxide for 7
days, and the nonadherent AF cells were removed. The me-
dium was then replaced twice weekly until the cells reached
70% confluence, when they were treated with 0.25% trypsin
and 1mM ethylenediaminetetraacetic acid (Invitrogen) for
3min. TheAF-derived stem cells (AFSCs)were collected and re-
plated in a split ratio of 1:3 under the same culture conditions.
Culture of DPSCs and osteogenic differentiation
Human DPs were extracted from adult teeth of healthy
subjects aged 21–45 years, according to our protocol.6 Briefly,
the pulp was gently removed and immersed in a digestive
solution: 3mg/mL type I collagenase plus 4mg/mL dispase
in phosphate-buffered saline (PBS) for 1 h at 378C. Once di-
gested, cells were immersed in the a-MEM culture medium
supplemented with 20% FBS, 100 mM 2P-ascorbic acid, 2mM
L-glutamine, 100U/mL penicillin, and 100 mg/mL strepto-
mycin (all purchased from Invitrogen).
At day 22 of culture, at least 1,000,000 cells per sample
were detached from the flasks and sorted for CD117, CD34,
and STRO-1 to obtain DPSCs. Sorted cells were cultured in a-
MEM with 20% FBS. When DPSCs showed signs of differ-
entiation, usually by day 30 as previously reported,6–8 cells
were examined under flow cytometry with the following
mouse anti-human antibodies: osteocalcin, CD44, and the
transcription factor RUNX-2 (all from Santa Cruz, Santa
Cruz, CA). For RUNX-2 intracellular analysis, cells were
stained with Caltag Fix & Perm Kit (Invitrogen) according to
the manufacturer’s instructions. CD44 and osteocalcin anti-
bodies were incubated for 30min at 48C in the dark. After
incubation, cells were rinsed and analyzed by flow cytome-
try. DPSCs, differentiated into osteoblasts and positive for
CD44, osteocalcin, and RUNX-2, were used for the coculture
experiments described below.
Cocultures of AFSCs and OCþRUNX-2þ DPSCs
At day 15 of culture, after cytometric analysis, samples of
100,000 AFSCs were plated in 16mm wells and cocultured
with 50,000 OC/RUNX-2-positive DPSCs, using 0.4 mm cell
culture inserts (Falcon-BD, Le Point de Clex, France). As
controls, MSCs were cultured with the osteogenic medium,
osteogenic medium supplemented with 10 ng/mL vascular
endothelial growth factor (VEGF) (Sigma–Aldrich, Milan,
Italy), and 20 ng/mL bone morphogenetic protein-2 (BMP-2)
(Sigma–Aldrich) and with the standard medium. Plated
cells were incubated at 5% CO2 for 30 days. The culture
medium contained 10 mg/mL a-ascorbic acid, 10mM b-
glycerophosphate, 100 nM dexamethasone, and gentamicin.
The medium was changed twice a week.
Stimulation of AFSCs with the conditioned medium
of OCþRUNX-2þ DPSCs
At day 15 of culture, after cytometric analyses, samples of
100,000 AFSCs were plated in 16mm wells and stimulated
with the conditioned medium (CM) prepared as follows:
after 3 days of culture with 1,000,000 OCþRUNX-2þ DPSCs,
the supernatant was collected and filtered through a 0.22 mm
strainer. AFSCs were then cultured with the CM for 15 and
30 days, changing the CM twice a week. Control samples
were cultured with the standard medium.
BMP-2 and VEGF enzyme-linked immunosorbent
assay analyses
To evaluate BMP-2 and VEGF levels in the CM, superna-
tant was collected from cultures at 24, 48, 72, and 96 h from
plating OCþRUNX-2þ DPSCs. CM aliquots were stored at
208C. After thawing at room temperature, 0.5mL was
collected from aliquots and analyzed with an ELISA kit for
BMP-2 and VEGF (R&D, Milan, Italy).
Immunofluorescence
AFSCs cultured in 24-well plates were fixed in 4% para-
phormaldeyde/1% Triton in PBS for 30min at 48C, washed
in PBS, treated with 5% milk for 60min at room temperature,
and then stained with primary antibodies at 48C over night.
The primary antibodies were the following: BMPR1, BMPR2,
BMP-2, CD29, CD34, CD44, CD90, CD117, CD133, OCT3/4,
SSEA-4, Tra1-60, Tra1-80, stemness markers, and osteocalcin
as an osteogenic marker. The secondary antibodies were
FITC- and PE-conjugated mouse antigoat (Santa Cruz) in-
cubated for 60min at 48C. The nuclei were stained with 40,
6-diamidino-2-phenylindole. Cells were then washed and
observed under the fluorescence microscope (Nikon TE 2000-
S, Milan, Italy). Isotypes and nonprobed cells were used as
controls.
Flow cytometry
After 15 days of culture in the standard medium, AFSCs
were analyzed by flow cytometry for the following antibodies:
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PE-conjugated mouse anti-human CD29, FITC-conjugated
mouse anti-human CD31, FITC-conjugated mouse anti-
human CD34, FITC-conjugated mouse anti-human CD44,
FITC-conjugated mouse anti-human CD45, PE-conjugated
mouse anti-human CD56, FITC-conjugated mouse anti-
human CD90, PE-conjugated mouse anti-human CD133, and
PE-conjugated mouse anti-human CD326. All antibodies
were purchased from BD Pharmingen (Buccinasco, Milan,
Italy) except CD133, which was purchased from Miltenyi
Biotec (Calderara di Reno, Bologna, Italy). The antibodies
were incubated for 30min at 48C in the dark. After incuba-
tion, the cells were washed and then analyzed by flow cy-
tometry at a FACSVantage with CellQuest software (Becton
& Dickinson, Mountain View, CA).
RT-polymerase chain reaction
Total RNA was extracted using TRIzol Reagent (Invitro-
gen) according to the manufacturer’s protocol. RNA con-
centration and purity were determined using an ultraviolet
spectrophotometer by A260 and A260/A280 ratio, respectively.
The integrity of total RNA was assessed on standard 1%
agarose/formaldehyde gels. The RNA samples were treated
with DNase I to remove residual traces of DNA. cDNA was
obtained from 1mg of total RNA, using reverse transcriptase
(Promega Italia Srl, Milan, Italy) and random primers (Pro-
mega) in a final volume of 20mL. cDNAs (1mL for each
sample) were amplified by polymerase chain reaction (PCR)
using the primer sequences as follows: BMP-2, 50-CGTG
TCCCCGCGTGCTTCTT-30 (sense) and 50-GGCTGACCTG
AGTGCCTGCG-30 (antisense); osteocalcin, 50-CCCTCAC
ACTCCTCGCCCTATT-30 (sense) and 50-AAGCCGATGTG
GTCAGCCAACTCGT-30 (antisense); osteonectin, 50-AAA
CCCCTCCACATT CCC-30 (sense) and 50-ATTTTCCGCC
ACCACCTC-30 (antisense); RUNX-2, 50-CAC TCACTA
CCACAC CTACC-30 (sense) and 50-TTCCATCAGCGTC
AACACC-30 (antisense). Thermal cycle parameters were as
follows: 958C for 2min, 35 cycles of 958C for 30 s, 528C–608C
(depending on the Tm of each individual set of primers) for
1min, and 728 for 30 s. GAPDH, 50-TGGACTCCACGACG
TACTCAG-30 (sense) and 50-ACATGTTCCAATATGATT
CCA-30 (antisense), was amplified as an internal control. The
reverse transcription (RT)-PCR products were separated on
2% agarose gel electrophoresis, stained with ethidium bro-
mide, and photographed under ultraviolet illumination.
Alizarin Red staining
Monolayers in 6-well plates (10 cm2/well) were washed
with PBS and fixed in 10% paraphormaldehyde (Sigma–
Aldrich) at room temperature for 15min. Monolayers were
then washed twice with excess dH2O before addition of 1mL
of 40mM Alizarin Red S (pH 4.1) per well. The plates were
incubated at room temperature for 20min with gentle
shaking. After aspiration of the unincorporated dye, the
wells were washed four times with 4mL dH2O while shak-
ing for 5min. The plates were then left at an angle for 2min
to facilitate removal of excess water. Stained monolayers
were observed by phase microscopy using an inverted mi-
croscope (Nikon). For quantification of staining, 10% acetic
acid was added to each well, and the plate was incubated at
room temperature for 30min with shaking. Calcium deposits
were orange-red.
Alkaline Phosphatase staining
Cells were fixed in 4% paraphormaldehyde in PBS for
20min and then incubated for 30min in TRIS Buffer (0.2M,
pH 8.3) with AS-MX phosphate (Sigma, St. Louis, MO) as a
substrate and Fast Blue (Sigma) as a stain. The alkaline
phosphatase (ALP)-positive cells stained blue/purple. Each
experiment was performed in triplicate.
Results
Cell cultures
DPSCs were sorted for CD117, CD34, and STRO-1. After
30 days of culture with the standard medium plus 20% FBS,
sorted cells expressed CD44, RUNX-2, and osteocalcin; had
an osteoblast-like morphology with the formation of typical
calcification nodules; and expressed mRNA transcripts for
bone extracellular matrix proteins, as previously demon-
strated by us.6,7 On the contrary, AF cells had a heteroge-
neous morphology consisting primarily of two cell types: one
was similar to fibroblasts, whereas the other was small and
rounded, resembling epithelial cells (Fig. 1). We were able to
expand AFSCs up to 2106 cells within 4 weeks (3 passages)
and culture them until the 30th passage. After this time, the
cells became large and flat, suggestive of senescent cells.
Phenotypic characterization of AFSCs
Before coculture experiments we performed immunoflu-
orescence and cytometric assays to confirm the stemness
characteristics of AF cells. Actually, AF cells expressed all the
markers commonly found on MSCs: cells were strongly
positive for BMP-2, BMPR1, BMPR2, SSEA4, CD29, CD44,
CD90, CD117, Tra1-60, Tra 1-80, and OCT3/4; had a weak
positivity for CD133 and CD146; and were negative for
CD34 and osteocalcin. Moreover, flow cytometry performed
after 15 days of culture in the standard medium revealed that
AFSCs expressed high levels of CD29 (98%), CD44 (94%),
CD56 (92%), and CD90 (96%) and low levels of CD133
(13%), and were negative for CD31, CD34, CD45, and CD326
FIG. 1. AF-derived stem cell morphology consisting of two
cell types: fibroblast-like (arrow 1) and small, rounded cells
(arrow 2). AF, amniotic fluid. Color images available online
at www.liebertonline.com/ten.
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(Fig. 2). This antigenic pattern confirmed the presence of
undifferentiated cells within AF, and the negativity for os-
teocalcin showed that an osteogenic fraction was not present
within the cell population.
AFSCs cocultured with DPSC-derived
osteoblasts or exposed to osteoblast-CM undergo
osteogenic differentiation
After 15 days of coculture the morphology of AFSCs be-
came homogeneous, consistently exhibiting a fibroblast-like
morphology until the end of the culture period. After 10 days
of coculture, AFSCs started to change their morphology and
their growth. In some areas of the culture plates, AFSCs were
seen to aggregate into groups, forming hemispheric centers.
After 20 days, these centers formed a rounded nodular
structure, and after 30 days of stimulation, calcification
nodules were clearly observable (Fig. 3A). These nodules
were 1–2mm in diameter and were dark at light microscopy
due to the density of the matrix (see Table 1).
Similar observations were made in the experiments using
CM stimulation. After about 15 days of exposure to the CM,
AFSCs started to change their morphology, building pseudo-
nodular structures that at day 30 became bone (Fig. 3B).
The AFSCs cultured in an osteogenic medium (Fig. 3C)
and in the same medium supplemented with VEGF and
BMP-2 produced nodular structures after 3 weeks of culture.
No nodular structures were observed in the plates of AFSCs
grown in the standard medium. After 16 days, the cells of
these cultures were confluent and remained heterogeneous,
FIG. 2. Immunofluorescence analyses on AF cells for mesenchymal markers showing a strong positivity for BMP2 (A),
BMPR1 (B), BMPR2 (C), SSEA4 (D), CD29 (E), CD44 (F), CD90 (G), CD117 (H), Tra1-60 (I), Tra 1-80 (J), and OCT3/4 (K), and
a weak positivity for CD133 (L) and CD146 (M) and cytometric analyses on AF-MSCs demonstrating high levels of CD29
(98%), CD44 (94%), CD56 (92%), and CD90 (96%), low levels of CD133 (13%), and negativity for CD31, CD34, CD45, and
CD326. Cells are stained with FITC or PE and double-stained with 40,6-diamidino-2-phenylindole. BMP2, bone morphoge-
netic protein-2; AF-MSCs, AF-derived mesenchymal stem cells. Color images available online at www.liebertonline.com/ten.
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with a round, fibroblast-like morphology, growing more
slowly compared to initial passages of cultures (Fig. 3D).
BMP-2 and VEGF quantitative detection
Enzyme-linked immunosorbent assays were performed at
24, 48, 72, and 96 h after plating to measure BMP-2 and
VEGF levels in the medium of OCþ/RUNXþ DPSCs. We
found that OCþ/RUNXþ DPSCs secreted high levels of
BMP-2 and VEGF, which increased with time. The level of
VEGF was 145.9 7pg/mL at 24 h and 411 13 pg/mL at
96 h ( p< 0.001) (Fig. 4A), whereas that of BMP-2 was
113.8 15pg/mL at 24 h and 193.4 20 pg/mL at 96 h ( p<
0.001), (Fig. 4B).
RT-PCR, Alizarin Red S, and ALP analyses
At 15 and 30 days of coculture, RT-PCR analyses revealed
that AFSCs cocultured with OCþ/RUNX-2þ cells were able
to differentiate into osteoblasts because of expression of
genes encoding for osteogenic markers such as BMP-2,
RUNX-2, osteocalcin, and osteonectin. The same results were
obtained in AFSCs stimulated with the CM of OCþ/RUNX-
2þ DPSCs and in AFSCs cultured in the osteogenic medium.
Interestingly, cells cultured in the osteogenic medium sup-
plemented with VEGF and BMP-2 showed a significant
RUNX-2 gene upregulation. Cells cultured in only the stan-
dard medium also expressed genes encoding for BMP-2 and
osteonectin. Moreover, they expressed high levels of mRNA
transcript of RUNX-2, but did not express mRNA transcript
for osteocalcin (Fig. 5A).
To confirm osteogenic differentiation of AFSCs cocultured
with OCþ/RUNX-2þ DPSCs and AFSCs cultured with the
CM of OCþ/RUNX-2þ DPSCs, Alizarin Red S and ALP
staining were performed. Alizarin Red S reveals calcium
accumulation within cells and ALP is an enzyme required for
mineral deposition. Cells from cocultures and those stimu-
lated with the CM showed Alizarin Red–positive condensed
nodules with high levels of calcium deposits; no staining was
seen in the control cultures grown in the standard medium
(Fig. 5B). ALP staining was clearly observable in bone nod-
ules and the surroundings cells, confirming their nature as
mineralization and ossification centers both in cocultures and
in CM experiments. AFSCs grown in an osteogenic medium
were positive for Alizarin Red S and ALP (Fig. 5C).
FIG. 3. Calcification nod-
ules in (A) AF-MSCs/DPSCs
cocultures; (B) in AF-MSCs
cultured in the conditioned
medium; (C) in AF-MSCs
cultured in the osteogenic
medium; (D) no nodular
structures were found in
AF-MSCs cultured in the
standard medium, after 30
days of culture. DPSCs,
dental pulp stem cells.
Table 1. Number of Bone Nodules and Percentages of Bone Differentiation in All Culture Conditions
No. of calcification nodules Percentage of bone differention
Culture conditions 15 days 30 days 15 days 30 days
AF-MSCs standar medium 0 0 0 0
AF-MSCs osteogenic medium 3 21 12 75
AF-MSCs osteogenic mediumþ bone morphogenetic
protein-2þvascular endothelial growth factor
7 20 17 77
AF-MSCs conditioned medium 15 32 41 91
AF-MSCs/dental pulp stem cells coculture 17 35 48 98
AF-MSCs, amniotic fluid-derived mesenchymal stem cells.
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Discussion
There is growing evidence on the presence of MSCs in
many tissues of the human body. AF is known to contain
multiple cell types derived from the developing fetus.17,18
Cells within this heterogeneous population can give rise to a
variety of differentiated cells, including those of adipose,
muscle, bone, and neuronal lineages.10,13,14 In this study, we
have demonstrated that AF progenitors can commit to the
osteogenic lineage when exposed to RUNX-2þ/OCþ cells
FIG. 5. (A) RT-polymerase
chain reaction analyses for
Runx-2, osteocalcin (OC), os-
teonectin (ON), and BMP-2,
in all culture conditions (I,
AF-MSCs grown in Dulbec-
co’s modified Eagle’s medi-
um; II, cocultured; III,
osteogenic medium added
with BMP-2 and VEGF; IV,





stimulated with the condi-
tioned medium, as well as
Runx-2 upregulation by
VEGF and BMP-2; (B) Ali-
zarin Red S and (C) alkaline
phosphatase staining for
AF-MSCs, in all culture con-
ditions, showing the osteo-
genic differentiation of
AF-MSCs. Color images
available online at www
.liebertonline.com/ten.
FIG. 4. Enzyme-linked im-
munosorbent assays per-
formed for (A) VEGF and (B)
BMP-2 released in the me-
dium by OCþ/Runxþ DPSCs
after 24, 48, 72, and 96 h after
plating. VEGF, vascular en-
dothelial growth factor.
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(obtained from the differentiation of human DPSCs in our
case), and when AFSCs were cultured with the CM of
RUNX-2þ/OCþ DPSCs. DPSCs are bone-committed cells
and form a good model of osteogenic differentiation that
can be used to study the regenerative mechanisms of the
bone.6–8,16,19 The ability to obtain osteogenic differentiation
and the production of a well-differentiated bone matrix by
culturing the cells with OCþ/RUNX-2þ cells and using the
CM of RUNX-2þ/OCþ DPSCs is very important in the per-
spective of clinical applications of these cells. Although DPSCs
are multipotent stem cells,6,20 their self-commitment toward
an osteogenic fate mimics the bone regeneration occurring
after injury. Indeed, this in vitro model has been shown to be
helpful in the study of the bone development processes.16,21 In
this study, we used OCþ/RUNX-2þ differentiated stem cells
instead of bone cell lineages to mimic the physiology of bone
differentiation microenvironment in terms of soluble factors
released during the differentiation process.
Before the coculture and CM stimulation experiments,
we performed immunofluorescence and cytometric assays
on AFSCs to evaluate their stemness and possible expres-
sion of osteogenic/endothelial/hematopoietic and epithelial
differentiation markers. AFSCs are positive for CD29,
CD44, CD56, CD90, CD117, CD146, SSEA4, and OCT3/4,
highlighting that they are MSCs with expression of several
early embryonic/fetal cells. In particular, > 90% of the AF
cells expressed the transcription factor OCT-3/4, which is
associated with maintenance of the undifferentiated state
and pluripotency of embryonic stem cells. CD117 is the re-
ceptor of stem cell factor, mainly expressed on hematopoietic
and mesenchymal cells. Its expression together with OCT3/
4, CD29, CD56, CD90, and SSEA4 is a clear indication of
MSCs stemness. Moreover, AF cells expressed characteristic
markers of embryonic germ cells and embryonic stem cells,
including Tra1-60 and Tra 1-80. Interestingly, AF cells con-
stitutively expressed BMP-2 and both receptors BMPRI and
BMPRII. This is likely due to an intrinsic plasticity addressed
toward an osteogenic lineage. Finally, these cells were also
positive, although to a lesser extent, for CD133, which is
another stemness marker, mainly expressed on neuronal,
epithelial, and MSCs.
The absence of osteocalcin underlines that no osteogenic
fraction/subsets were present within the tested cell popula-
tion; in addition, CD31, CD34, and CD45 negativity indicates
that AFSCs do not belong to the hematopoietic and endo-
thelial lineages. Moreover, AFSCs were negative for CD326
(also termed EpCAM), an epithelial lineage marker, con-
firming thus their mesenchymal origin.
Taking all these findings into consideration, we performed
cocultures to evaluate the effects of OCþ/RUNX-2þ DPSCs
on AFSC differentiation. After 20 days of coculture, we ob-
served that AFSCs first formed aggregates and then devel-
oped hemispheric ossification centers that grew into rounded
structures that were macroscopically detectable. At the same
time, we cultured AFSCs in the CM derived from OCþ/
RUNX-2þ DPSCs to evaluate the effect of soluble factors
produced by OCþ/RUNX-2þ DPSCs on osteogenic differ-
entiation of AFSCs. After 30 days of exposure to the CM,
calcification nodules were observed in plates as observed by
light microscopy.
To further demonstrate the ability of DPSCs to differen-
tiate into bone, we performed RT-PCR and Alizarin Red S
and ALP staining after 15 and 30 days coculture or CM
stimulation. The appearance of a mineralized matrix was
clearly observed both with Alizarin Red and ALP staining,
which specifically stains calcium deposits, demonstrating
that AFSCs were able to differentiate into osteoblasts. This
was confirmed by RT-PCR for BMP-2, osteocalcin, osteo-
nectin, and RUNX-2 transcripts. Interestingly, we detected
high levels of RUNX-2 and low levels of osteonectin in cul-
tures in which AFSCs grew in a standard medium, showing
that RUNX-2 and osteonectin themselves were not able to
effectively induce bone differentiation. Only AFSCs were
capable of achieving an effective osteogenic fate, as evi-
denced by the positivity for osteocalcin, which is a marker of
terminal osteoblast differentiation and bone formation. Fur-
ther, AFSCs grown in a standard medium, although ex-
pressing genes encoding for osteogenic markers, did not
produce nodular structures during the culture period,
maintained a heterogeneous fibroblast-like morphology, and
were not stained by Alizarin Red S.
RUNX-2 is a transcription factor involved in osteogenic
differentiation and its expression decreases during terminal
osteoblast differentiation. In the cocultures, RUNX-2 levels
decreased when compared to cells cultured alone. This
finding, together with osteocalcin expression, indicates that
osteogenic differentiation takes place and suggests different
roles of these genes in the regulation of bone formation. In
this context, it is very important to consider the role of sol-
uble factors released from DPSCs into the coculture medium,
CM, and osteogenic medium supplemented with VEGF and
BMP-2 that might induce osteogenic differentiation of
AFSCs. There is evidence demonstrating that several soluble
proteins extracted from human teeth regulate odontogenesis
and mineral formation,22,23 such as BMPs, enamelin, decorin,
bone sialoprotein, and fibronectin. In this context, we eval-
uated both the BMP-2 and VEGF levels in OCþ/RUNX-2þ
DPSCs medium and the effect of BMP-2 and VEGF on os-
teogenic differentiation. BMP and VEGF are two important
factors for osteogenesis. BMP-2 is a member of the trans-
forming growth factor superfamily and plays an essential
role during skeletal development and growth. BMP-2 is also
used widely for therapeutic bone applications. VEGF is a
heparin-binding glycoprotein with strong angiogenic and
mitogenic activities.24–26 VEGF is an endothelial cell mitogen
in vitro, while in vivo acts as a chemotactic factor for mono-
cytes and osteoblasts can induce angiogenesis and increase
microvascular permeability.27 In addition, VEGF is of critical
importance for bone development as vessel formation is di-
rectly linked to bone differentiation.28 By their involvement
in osteogenic processes and angiogenesis, these factors can
influence the biological responses and bone differentiation
programme.
In this study, BMP-2 and VEGF released into the medium
by OCþ/RUNX-2þ DPSCs may be responsible for the bone
differentiation of AFSCs. In our experiments, AFSCs, when
cultured as reported above, seem to be able to induce bone
differentiation and they may provide an excellent alterna-
tive source of human MSCs with potential therapeutic ap-
plications. Interestingly, VEGF and BMP-2 morphogens,
when added to the osteogenic medium, were able to pro-
mote osteoblastic differentiation/maturation by upregulat-
ing expression of RUNX-2, as confirmed by RT-PCR.
Further investigations are needed to fully assess this
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possibility. On the other hand, DPSCs have already been
used successfully with titanium implants20 for several ap-
plications in humans, such as bone defect repair.19 Hope-
fully, MSCs may be used in the near future for heterologous
transplants, due to their unique outstanding features.29,30 In
this view, the ability of osteoblasts that have been differ-
entiated from DPSCs to induce AFSCs to form bone is a
further possibility that can be taken into consideration for
clinical applications.
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